LYMPHOMAS

Justine Kahn, MD, MS, discusses the Children’s Oncology Group study that identified a survival disparity among patients with de novo Hodgkin lymphoma of different races and economic statuses.

Bristol Myers Squibb has decided to withdraw the approval for romidepsin, a histone deacetylase inhibitor, for the treatment of adults with peripheral T-cell lymphoma who received at least 1 prior therapy after a confirmatory phase 3 study missed its primary end point.

Camidanlumab tesirine is a potential treatment option for relapsed or refractory lymphoma with a tolerable safety profile, particularly in patients with classical Hodgkin lymphoma.

Matthew A. Lunning, DO began a Case-Based Roundtable event by asking a group of oncologists how diffuse large b-cell lymphoma in handling in their practices. The responses varied, considering some of the oncologists worked in academic centers and some worked in the community setting.

Treatment with mogamulizumab-kpkc in adult patients with cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome, demonstrated better outcomes in those who had higher levels of blood involvement at baseline assessment, according to results of a post-hoc analysis for the MAVORIC trial.

Laurie Sehn, MD, discusses the unmet needs and future directions in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.

Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.

An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.

Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.

Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.

Encouraging findings from an ongoing phase 1 trial evaluating an off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy, evaluated in patients with lymphoma.

Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.

A supplemental new drug application has been submitted to the FDA seeking approval for the combination of copanlisib and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s Lymphoma and is outside of the FDA accelerated approved indication for the treatment of relapsed follicular lymphoma who have received at least 2 prior systemic therapies.

Following rituximab resistance, the combination of lenalidomide and rituximab led to durable improvements in outcome for patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas, even after 10 years of follow-up, according to long-term results presented at the European Hematology Association 2021 Congress.

A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.

Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.

Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.

A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

A second-generation 4chimeric antigen receptor (CAR) T-cell agent has induced responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated in a phase 1 study.

Increased efficacy was observed with the combination of mosunetuzumab with polatuzumab vedotin in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

The FDA has accepted a supplemental new drug application for zanubrutinib for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20-based therapy. The agent was also granted priority review, with a Prescription Drug User Fee Act target action date of September 19, 2021.

Regeneron is resuming enrollment of patients with follicular lymphoma and diffuse large B-cell lymphoma in monotherapy trial of odronextamab after the FDA lifted the partial clinical hold placed on the agent in December 2020.

The LOTIS-2 phase 2 study of loncastuximab tesirine continued to show durable responses and tolerability in relapsed or refractory patients with DLBCL, according to the most recent published results.

Zanetta Lamar, MD, discussed the efficacy of tafasitamab in combination with lenalidomide in the clinical trial setting.

Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.